© Arbovax Inc 2008-2010 Arbovax Arbovax ® Advanced technology for insect-borne virus vaccines.

© Arbovax Inc 2008-2010

Arbovax ®

Advanced technology for insect-borne virus vaccines


Arbovax has a unique technology that modifies arthropod-borne viruses (arboviruses) preventing them from replicating in mammalian cells. The result is a distinct and novel platform approach to vaccine development.


Arbovirus Vaccine Market

• Total annual market exceeds $1.0 billion– Market comprised of endemic populations,

military personnel and travelers to affected areas (c. 50MM persons/year, 2.5-3 billion at risk)

– Dengue: $0.5- 1.0+ billion– Sanofi “next blockbuster - €1

billion/year” – West Nile: $300 million– Japanese Encephalitis: $300 million– Yellow Fever: $50 million– Chikungunya: $50 million

– Now a threat in Asia and Europe


“From Swine Flu to Dengue Fever: Infectious Disease Risks on the Rise (Emory University 2009) “Fourth consecutive year of unusually high infection rates” (WHO, 2008)

“Vagabond Virus” Dengue fever is spreading and some think climate change is to blame… (Time, Dec 2007)

Brazil 2008: 87 deaths and 93,000 sickened


• Arbovax is ideally positioned to take advantage of the increased interest in adult vaccines by large pharmaceutical companies and their continuing investment in biotechnology companies

• Both Merck and Novartis building vaccine plants in North Carolina.

• Recent acquisitions in the $300-500 million range e.g. • Intercell AG by Novartis 2007• Acambis by Sanofi 2009

• Arbovax offers potential for high value exit in a similar range through acquisition or out-licensing in 3-5 years

Opportunity


• Initial Target – Dengue Fever– Develop modified virus through mouse and

primate testing to phase I clinical trials– Seek corporate partner(s) to conduct trials,

manufacture and market final product

• Development of Additional Targets– West Nile, Chikungunya, Japanese

Encephalitis, Yellow Fever– Equine and livestock applications, offers

potential for veterinary spin-off

Business Model


Technology• Platform Technology

– Potential to address all 200+ insect-borne viral diseases

– Produces modified virus that will reproduce in insect cells but not mammalian cells

– Resulting virus produces strong immune response without onset of disease

• Initial Proof of Principle completed using Sindbis arbovirus– Produced protective immunity in mice

• Strong IP 3 issued patents cover worldwide commercialization of the technology

© Arbovax Inc 2008-2009M

T-1

MT-

2

ET-1

ET-2

Capsid

Envelope

RNARNA

Arbovax Platform Technology

Arbovax technology targets only the transmembrane portion of the virus retaining all other immunologically important characteristics

“Host-Range Mutation”


• Three Dengue 2 Host-Range mutants tested in mouse model

• Showed excellent neutralizing antibody response– These will be tested in non-human primate

model in April 2010 to demonstrate actual protection

• Dengue 1,3&4 will mirror Dengue 2 protection– Follow same development pathway

Dengue Fever


Mouse Data

• Mice injected with 29µg total protein – (approx 102-103 ffu/mouse)• Both mutants generate higher immune response than WT; this is consistent

with Sindbis data.


Competitive AdvantageCompany Technology

Arbovax Host-Range Mutation

GSK/WRAIR Live Attenuation

NIHCDC/Inviragen/ShantaSanofi-Pasteur

Chimera

Hawaii biotech Subunit

Cytos VLP


Competitive AdvantageTechnology Attributes

Host-Range Mutation

Single shotLong lived protection-provides all epitopes of virus No reversion to wild typeCost effective

Live Attenuation Requires multiple shotsRisk of reversion to wild typeLimited protection

Chimera Requires multiple shotsLimited protectionCostly

Subunit Requires multiple shotsLimited protectionCostly

VLP Very early stage


Malcolm Thomas, Founder, President & CEO Stemco, Guava, Bayer Biologicals, Becton DickinsonVP/GM BD Asia Pacific $50MM Regional Business Unit

Jonathon Lawrie Ph.D., Founder & Director Venafair, Stemco, Cardiovascular Diagnostics, Codon, Becton Dickinson, Roche Diagnostics

Dennis Brown Ph.D., Founder Professor and Department Head of Molecular & Structural Biochemistry at North Carolina State University since 1997

Kathy Smith PhD, Senior Scientist Molecular biologist UVA

Kavita Nanda PhD, Senior ScientistBiochemist NCSU

Team


Initial Round $1.5 million• Piedmont Angel Network• Research Development Foundation• Mario Family Partners• Jefferson Corner Group• Management

Additional support:• NC Biotechnology Center

Series A Funding


• Jan 2008 – 4800 sq/ft laboratory near NC State• Over 50 Dengue 2 modifications produced to date • Signed 5 year CRADA with US Army

• Dengue & West Nile

• Joint research agreement with Immunobiosciences Inc

• West Nile and Chikungunya development initiated– NCSU BL3 facility

– 3 federal grant applications submitted– Tested Dengue 2 clones in mouse model

Series A Milestones


Series B Funding

$2.0 million at pre-money of $4.0 million

• Dengue 2 non-human primate testing• Dengue 1,3,4 deletion mutant development• Dengue mouse testing and serotype optimization• Chikungunya and West Nile animal testing


Summary

• Experienced management team• Innovative, proprietary platform technology• Proof of principle completed• Market size >$1.0 billion• Committed inside investors• High value exit expected within 3-5 years• North Carolina qualified business venture

Date post:	16-Dec-2015
Category:	Documents
Upload:	christina-shelton
View:	214 times
Download:	0 times

© Arbovax Inc 2008-2010 Arbovax Arbovax ® Advanced technology for insect-borne virus vaccines.

Documents